Modeling of amplification by overexpression of wild-type RET sequence validates that RET overexpression, similar to RET fusions, can lead to aberrant downstream signaling like other RTKs such as ERBB2 amplification in breast cancer or MET amplification in lung cancer. Here, ERBB2 is linked to lung carcinoma.